医学
内科学
肝细胞癌
肝硬化
队列
慢性肝炎
置信区间
乙型肝炎
病因学
回顾性队列研究
胃肠病学
队列研究
肝病
慢性肝病
丙型肝炎
病毒性肝炎
阶段(地层学)
癌症
肝癌
乙型肝炎病毒
疾病
子群分析
肝病学
年轻人
存活率
生存分析
肝炎
多元分析
治疗
癌
作者
Shao-Li Huang,Hsi‐An Chen,Chun‐Hsun Liao,Shih-Chi Hu,Shang‐Chin Huang,Chun‐Jen Liu,Tung‐Hung Su,Jia‐Horng Kao
摘要
BACKGROUND: As hepatocellular carcinoma (HCC) etiologies shift from viral to non-viral, many at-risk patients lack surveillance in real-world practice. This study characterizes the clinical features and receipt of curative therapy in HCC patients with and without surveillance. METHODS: A retrospective cohort study was conducted at National Taiwan University Hospital (2015-2025). Patients newly diagnosed with HCC who had not undergone regular surveillance (n = 50) were compared with a consecutive surveillance-diagnosed cohort (n = 100). Subgroup analyses were performed in patients with chronic hepatitis B and MASLD. RESULTS: Compared with the surveillance group, non-surveillance patients had higher baseline liver enzymes and alpha-fetoprotein levels, larger tumors, higher rates of multifocal tumors, and more frequent vascular invasion. Symptomatically diagnosed non-surveillance patients also presented with more advanced disease. Multivariable analysis identified surveillance as a strong independent predictor of receiving curative therapy (odds ratio [OR]: 17.78; 95% confidence interval [CI]: 5.56-56.88, p < 0.001). In the chronic hepatitis B subgroup, both surveillance (OR 26.79, 95% CI: 6.80-106.00, p < 0.001) and higher BMI (OR 1.18, 95% CI: 1.05-1.33, p = 0.005) were independent predictors of curative therapy. The rate of HBV carriers (72%), cirrhosis (54%), and MASLD (14%) remained substantial within the non-surveillance group. CONCLUSION: HCC surveillance was associated with earlier stage at diagnosis and independently predicted receipt of curative therapy; higher BMI was an additional predictor in the HBV subgroup. Most patients diagnosed without surveillance had underlying HBV infection, cirrhosis or MASLD, and presented with more advanced disease and lower rates of curative therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI